Seeking Alpha

The FDA has rejected Depomed's (DEPO) gabapentin drug for treating hot flashes associated with...

The FDA has rejected Depomed's (DEPO) gabapentin drug for treating hot flashes associated with the menopause, as the risks - such as the prompting of suicidal thoughts - outweigh the benefits. Depomed will now stop developing gabapentin for menopause hot flashes; under the brand name Gralise, the medicine is already authorized to treat pain from shingles. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector